Whitehawk Therapeutics (WHWK) Insider Maroun Buys 38,040 Shares

On June 12, 2026, Richard Maroun participated in a significant wave of insider buying at Whitehawk Therapeutics, Inc. (WHWK). Maroun acquired 38,040 shares of the company, which trades on the Nasdaq. This purchase was not an isolated event; it was part of a broader cluster of buying activity where six different insiders each picked up the exact same amount of stock on the same day.

Unified Insider Activity at Whitehawk

The coordinated buying on June 12, 2026, involved several members of the leadership team. Along with Richard Maroun, insiders Mohammad Hirmand, Behzad Aghazadeh, Baiteng Zhao, Emma Reeve, and Neil Desai each purchased 38,040 shares. None of these transactions were made under a Rule 10b5-1 trading plan, which is a tool insiders sometimes use to schedule trades ahead of time. This collective move suggests a shared sentiment among the company's decision-makers during the June period.

Whitehawk Stock Performance

On Monday, the stock was priced at $4.16. This price point puts the company toward the higher end of its range over the last year, where it has seen a low of $1.82 and a high of $5.49. While the stock is currently trading just under its 50-day moving average of $4.29, it remains well above its 200-day moving average of $3.71. With a market value of roughly $230.3 million, the company is often watched for its clinical-stage developments rather than short-term price swings.

Analysts Set New Price Targets

Several research firms have weighed in on the stock recently with optimistic outlooks. On October 1, 2026, Stifel started its coverage of the company with a Buy rating and a $9.00 price target. This followed a similar move by Leerink Partners on July 13, 2026, which initiated an Outperform rating with a $9.00 target. B. Riley Securities also signaled confidence on June 25, 2026, setting a Buy rating and the highest price target among the group at $10.00. Currently, six analysts following the stock have a consensus Buy recommendation, with an average price target of $7.50.

Financial Health and Next Earnings

Whitehawk is a clinical-stage oncology company that focuses on developing antibody drug conjugates to treat various forms of cancer. Because it is still in the stage of developing its portfolio, the company is not yet profitable and does not have a meaningful P/E ratio. Its most recent data shows a return on equity of -44.98% and an earnings per share of -$1.21. Investors are likely looking toward November 5, 2026, when the company is scheduled to release its next set of quarterly financial results.

What's Ahead for WHWK

The cluster of insider buying in June provides a snapshot of how the company's leadership viewed the stock's value at that time. While these transactions are now several months old, they remain a key data point for those tracking internal confidence. The upcoming November earnings report will be the next major milestone for shareholders to see if the company's clinical progress matches the optimism shown by its board and executives.